Abstract
Background: An estimated two-thirds of medications prescribed for use in pediatric patients have not been proven safe or effective for this patient population. Since 1995 a dozen orally administered diabetes medications or combination of medications for the management of type 2 diabetes mellitus have been approved by the Food and Drug Administration. Of these, only one (metformin) is approved for use in pediatrics. As the prevalence of children diagnosed with type 2 diabetes continues to rise, the need for adequate information regarding the safety, efficacy, and appropriate dosing of oral diabetes medications in the pediatric population likewise increases. Objective: The purpose of this paper is to present the data available regarding the use of oral diabetes medications in a pediatric type 2 diabetes population. Methods: A computerized literature search was performed using Medline and the Cochrane Database of Systematic Reviews. Results: The Table consists of a summary of data regarding the use of oral antidiabetic agents in pediatric patients. These data include information regarding drug safety and efficacy and/or drug pharmacokinetic and drug dosing information. Conclusions: Data concerning the safety and efficacy of oral diabetes medications to treat type 2 diabetes of the young is limited. Data currently available support the use of metformin as first-line drug therapy. Results of prospective studies over the next three to five years will better define the role of thiazolidinedione use as initial therapy in pediatric type 2 diabetes patients.
Keywords: type 2 diabetes, pediatric, pharmacotherapy, safety, efficacy, medications
Current Diabetes Reviews
Title: The Utility of Oral Diabetes Medications in Type 2 Diabetes of the Young
Volume: 1 Issue: 1
Author(s): Michael P. Kane, Asim Abu-Baker and Robert S. Busch
Affiliation:
Keywords: type 2 diabetes, pediatric, pharmacotherapy, safety, efficacy, medications
Abstract: Background: An estimated two-thirds of medications prescribed for use in pediatric patients have not been proven safe or effective for this patient population. Since 1995 a dozen orally administered diabetes medications or combination of medications for the management of type 2 diabetes mellitus have been approved by the Food and Drug Administration. Of these, only one (metformin) is approved for use in pediatrics. As the prevalence of children diagnosed with type 2 diabetes continues to rise, the need for adequate information regarding the safety, efficacy, and appropriate dosing of oral diabetes medications in the pediatric population likewise increases. Objective: The purpose of this paper is to present the data available regarding the use of oral diabetes medications in a pediatric type 2 diabetes population. Methods: A computerized literature search was performed using Medline and the Cochrane Database of Systematic Reviews. Results: The Table consists of a summary of data regarding the use of oral antidiabetic agents in pediatric patients. These data include information regarding drug safety and efficacy and/or drug pharmacokinetic and drug dosing information. Conclusions: Data concerning the safety and efficacy of oral diabetes medications to treat type 2 diabetes of the young is limited. Data currently available support the use of metformin as first-line drug therapy. Results of prospective studies over the next three to five years will better define the role of thiazolidinedione use as initial therapy in pediatric type 2 diabetes patients.
Export Options
About this article
Cite this article as:
Kane P. Michael, Abu-Baker Asim and Busch S. Robert, The Utility of Oral Diabetes Medications in Type 2 Diabetes of the Young, Current Diabetes Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573399052952569
DOI https://dx.doi.org/10.2174/1573399052952569 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease
Current Pharmaceutical Design Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Antioxidant and Anti-hyperglycemic Activity
Current Topics in Medicinal Chemistry Riboregulators and Metabolic Disorders: Getting Closer Towards Understanding the Pathogenesis of Diabetes Mellitus?
Current Molecular Medicine Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women
Current Vascular Pharmacology Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity
Current Diabetes Reviews Inappropriate Antidopaminergic Drug Use in Parkinson’s Disease Inpatients
Current Drug Therapy Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Current Genomics Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Inflammasomes in the Pathophysiology of Maternal Obesity: Potential Therapeutic Targets to Reduce Long-Term Adverse Health Outcomes in the Mother and Offspring
Current Vascular Pharmacology In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease
Current Medicinal Chemistry Therapeutic Approach on AGE-RAGE Interaction and Its Function in Diabetic Inflammation Process
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response
Current Pharmaceutical Design Cocoa Polyphenols: Evidence from Epidemiological Studies
Current Pharmaceutical Design From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry